Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction
|
|
- Paula Rose
- 5 years ago
- Views:
Transcription
1 British Journal of Clinical Pharmacology DOI: /j x Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction Johanna Strandell, 1,2 Andrew Bate, 1,3 Staffan Hägg 2 & I Ralph Edwards 1 1 The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden and 2 Division of Clinical Pharmacology, Sahlgrenska University Hospital, Göteborg, Sweden, and 3 School of Information Systems, Brunel University, Uxbridge, UK WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Rhabdomyolysis is a serious but rare adverse effect of statins. The mechanism of rhabdomyolysis with statins is poorly defined, but the occurrence is known to increase with dose/ concentration. Some macrolides are known to interact with statins; however, azithromycin has not been described to interact with statins with the exception of two literature case reports. WHAT THIS STUDY ADDS A case series in the World Health Organization Adverse Drug Reaction (WHO-ADR) database was suggestive of a possible drug interaction between statins and azithromycin with rhabdomyolysis. A disproportionality measure, Omega, was shown to identify previously not recognized suspected drug interactions within the WHO-ADR dataset. Correspondence Johanna Strandell, MSc Pharm, The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Box 1051, SE Uppsala, Sweden. Tel: Fax: johanna.strandell@who-umc.org Keywords adverse drug reaction reporting systems, azithromycin, disproportionality measure, drug interaction, statins, WHO-ADR database Received 23 March 2009 Accepted 8 May 2009 AIMS In a systematic screening of the World Health Organization Adverse Drug Reaction database, VigiBase, in July 2008, a measure of association used to detect interactions (Omega) highlighted azithromycin with the individual statins atorvastatin, lovastatin and simvastatin and rhabdomyolysis. The aim was to examine all reports including rhabdomyolysis-azithromycin and statins in VigiBase to assess if the data were suggestive of an interaction. METHODS The individual case reports in VigiBase and the original files were reviewed. In order to investigate the reporting over time for rhabdomyolysis with azithromycin and statins to VigiBase, Omega values were generated retrospectively. RESULTS The reporting over time showed that rhabdomyolysis under concomitant use of azithromycin and statins was reported more often than expected from 2000 and onwards in Vigibase. After exclusion of possible duplicates and follow-up reports, 53 cases from five countries remained. Rhabdomyolysis occurred shortly after initiation of azithromycin in 23% of cases. In 11 patients an interaction had been suggested by the reporter. With the exception of one patient, the statin doses reported were within the recommended daily doses. CONCLUSIONS Case reports in VigiBase are suggestive that interactions between azithromycin and statins resulting in rhabdomyolysis may occur. This analysis showed the potential of the newly developed disproportionality measure, Omega, which can help to identify drug interactions in VigiBase in the future. The results also showed that reviewing spontaneous reports can add information to drug interactions not established previously The Authors Journal compilation 2009 The British Pharmacological Society Br J Clin Pharmacol / 68:3 / / 427
2 J. Strandell et al. Introduction In general, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are well tolerated by most users [1, 2]. However, the clinical syndrome rhabdomyolysis has been demonstrated to be a rare but potentially life-threatening adverse effect of statins [3]. The mechanism of rhabdomyolysis with statins is poorly defined, but the occurrence is known to increase with dose/ concentration [4]. Consequently, the risk increases when drugs that exclusively can cause rhabdomyolysis are used concomitantly with other drugs that can increase their effects via interactions. The macrolides erythromycin, clarithromycin, troleandomycin and telithromycin have been mentioned as potential interacting agents with statins in standard drug references [5, 6] since they are cleared through the same metabolic pathway, CYP3A4. The newer macrolide, azithromycin, is not suggested to cause clinically significant interactions with agents cleared through the cytochrome P450 enzyme system [7, 8]. Only one small human study has suggested that statins and azithromycin do not interact [9]. In that study 500 mg azithromycin used once daily orally for 3 days had no effect on pharmacokinetic parameters, such as AUC and C max of atorvastatin in 12 healthy volunteers. There are two case reports suggesting an interaction between azithromycin and statins [10, 11]. In the first case development of rhabdomyolysis was observed in a 51-year-old man using lovastatin the day after a completed 5-day course of azithromycin [10]. In the second case a 56-yearold man using simvastatin in combination with several other drugs, including the CYP3A4 inhibitor nefazodone developed rhabdomyolysis 5 days after the initiation of azithromycin [11]. Data mining methods [12, 13] have been extensively used in routine signal detection [14] of single drug adverse drug reaction (ADR) combinations in pharmacovigilance. Measures of disproportionality have also been proposed in order to detect drug interactions [15 17]. Recently a disproportionality measure (Omega) was developed to study the co-reporting of two drugs and one ADR in order to detect drug interactions [18] in the World Health Organization (WHO)-ADR database, called VigiBase [19]. Since the statistical foundation of the method [18] and its ability to highlight interactions [18, 20] have been demonstrated, we have started to use the method in order to screen systematically for emerging drug interactions. In July 2008 the first systematic screening of VigiBase was done. In this screening the statistical measure was positive for atorvastatin, lovastatin and simvastatin with azithromycin and rhabdomyolysis. As this possible interaction has not previously been well described, we analysed the reporting of this potential interaction between azithromycin and statins in VigiBase. Method The WHO Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (UMC), based in Uppsala, Sweden, collects spontaneously reported cases of suspected ADRs. These reports are forwarded from national centres in 86 countries [21]. The case reports are recorded in a common format, and processed and stored in a database, referred to as VigiBase [21]. Over 4 million case records are currently maintained by the centre, which provides a unique source of international ADR information. Each case report includes at least one drug suspected of causing the ADR, one ADR, reporting country and an identification number. Even though the data are not homogeneous with respect to origin or the probability that the pharmaceutical product caused the adverse reaction, spontaneous reporting of suspected ADR reports remains the cornerstone in the early detection of signals of previously unknown ADRs for one drug. Today quantitative screening is often an integral part of an overall knowledge discovery process for the detection of previously unsuspected ADRs in large collections of spontaneous reports [22]. There are several measures of pairwise association used to screen collections of spontaneous reports for excessive reporting of single drug single adverse reaction combinations. In routine signal detection, the UMC uses the Information Component (IC) measure of association [12]. The IC is a logarithmic measure based on the observed-to-expected ratio for the number of reports on a drug and an ADR together, where the expected number is based on the total number of reports on the drug and the overall relative reporting rate of the ADR in the entire database. It is a Bayesian implementation of the observed-toexpected ratio, with a prior assumption of independence between drug and adverse reaction. The algorithm includes shrinkage of the observed-to-expected ratio towards the independence assumption when there is limited amount of data and observed and expected counts are small; effectively, this reduces the number of falsepositive associations with little data support. The IC is used to filter out combinations of particular drugs and ADR combinations that are present more frequently than expected according to the reporting of all reports for the particular drug and ADR and the total number of reports in VigiBase. The IC measure in conjunction with triage filters [23, 24] generates a list of drug ADR combinations that are believed to be of greatest importance. This process is run quarterly on VigiBase. The drug ADR combination characteristics of the quarterly search include positive IC credibility intervals, drugs recently marketed (introduced in the WHO Drug Dictionary within the last 5 years), serious reactions (critical terms within WHO- Adverse Reaction Terminology [19]), reported from more than one country and rapidly increasing IC value. 428 / 68:3 / Br J Clin Pharmacol
3 Azithromycin-statin interaction The analysis presented in this study is based on a measure of interaction, related to the IC, which is referred to as Omega, and contrasts the observed relative reporting rate in the database with its expected value estimated from the relative reporting rates of the ADR given and with the individual reporting of each drug. The observed number of cases is the number of reports reported to Vigi- Base for the two drugs together, with the ADR of interest. The expected number of cases is the number of reports, which we expect to be reported for the drug drug ADR (DDA). No measure has yet been shown effective in highlighting emerging drug drug interactions.this is at least in part due to limitations in the choice of measures used. However, a measure where the expected count is based on an additive model [25] will be more likely to highlight signals of drug drug interactions. Such additive baseline models have proven more effective as a basis for drug drug interaction surveillance than the multiplicative models on which standard methods such as log-linear models and logistic regression are based [18, 25]. If the Omega value is greater than zero the DDA is reported more often than expected. The measure is described in detail in by Norén et al. [18]. The lower limit of the 95% credibility interval provides a measure of the robustness and is called Omega_025, and Omega_025>0 is used as a threshold to screen for reporting patterns suggestive of drug drug interaction. The credibility intervals become narrower when more information is added to the database in the form of case reports on the DDA. Narrow credibility intervals indicate the robustness in the reported value. In the systematic screening of VigiBase in July 2008 some of the triage criteria used in routine signal detection were used. Atorvastatin, lovastatin and simvastatin were all reported more frequently than expected with azithromycin and rhabdomyolysis. The case reports within the database originated from more than one country. A more extensive search on rhabdomyolysis, azithromycin and all statins was then performed in order to investigate further the possible interaction. The case reports in VigiBase and original files, which generally provide more detailed information in the form of narrative text for the individual case report, were reviewed clinically. To investigate the evolution in time of the reporting pattern in VigiBase, Omega values and corresponding 95% credibility interval limits were computed for retrospectively recreated versions of VigiBase for rhabdomyolysis with azithromycin coreported with all statins combined. Duplicate reports and follow-up reports are present in VigiBase and are identified by an automatic [26] or manual screening process. These reports were included in the calculation of Omega since both the observed and expected counts should be inflated by the same magnitude assuming absence of differential rates of duplication. However, these reports were excluded in the detailed case analysis. Results In a systematic screening of VigiBase in July 2008 the associations of rhabdomyolysis with azithromycin atorvastatin, lovastatin and simvastatin were quantitatively highlighted. These findings prompted a more extensive analysis of azithromycin and all statins with rhabdomyolysis. Table 1 provides a summary of the statistical information provided for the 58 cases of rhabdomyolysis reported with azithromycin and one of the following statins: atorvastatin, cerivastatin, lovastatin, pravastatin, rosuvastatin or simvastatin. Fluvastatin was the only individual statin never co-reported to VigiBase with azithromycin and rhabdomyolysis. Other macrolides co-reported with any statin and rhabdomyolysis to VigiBase were clarithromycin (n = 118), erythromycin (n = 36), roxithromycin (n = 7) and telithromycin (n = 8). At the time of the study VigiBase included almost 4 million case reports, of those concerned approximately statins. Rhabdomyolysis was Table 1 The reporting for rhabdomyolysis with azithromycin for each individual statin in VigiBase up to July 2008 Statin Observed DDA Expected DDA Omega Omega_025 IC for statin-rhabdo 2008q2 IC_025 for statin-rhabdo Atorvastatin Cerivastatin Lovastatin Pravastatin Rosuvastatin Simvastatin All statins DDA, drug drug ADR (represents azithromycin with the individual statin and rhabdomyolysis); Observed, the observed number of cases represents the number of reports actually reported to VigiBase for the two drugs together with the ADR of interest; Expected, the expected number of cases is number of reports which we expect to be reported for the drug drug ADR (DDA). The expected count is dependent on the total number of reports in VigiBase, per individual drug, for the combination of the two drugs and the ADR of interest; Omega, measure of disproportionality used to screen Vigibase for possible emerging drug drug interactions; IC, measure of disproportionality used to screen Vigibase for possible emerging ADR side-effects. Br J Clin Pharmacol / 68:3 / 429
4 J. Strandell et al. Table 2 Descriptive data for the 53 patients reported with rhabdomyolysis with azithromycin and statins Statin Tot reports No of. countries reporting Age range Dose range Solely two drugs Overlapping therapy of statins and azithromycin Atorvastatin mg (n = 10) 6 4 Cerivastatin mg (n = 10) 2 4 Lovastatin * 0 0 Pravastatin mg (n = 1) 0 1 Rosuvastatin mg (n = 2) 0 2 Simvastatin mg (n = 11) 4 1 *Age was provided in only one patient. n, the number of patients where dose information was provided. reported to the database on reports, >9000 of which concerned statins, with the majority including cerivastatin. In July 2008 VigiBase contained approximately reports of azithromycin. Subsequent to the initiation of the clinical review, four additional case reports were entered to the database of azithromycin and statins rhabdomyolysis.when duplicates and follow-up reports were excluded, 53 cases were reviewed. In six cases, two or more statins were coreported. The cases were reported from five countries: Canada (n = 3), France (n = 1), Germany (n = 1), Switzerland (n = 2) and the USA (n = 46). Table 2 includes a summary of all 53 patients. The age range was years (median 60 years). Fourteen (26%) patients had been using the statin for 3 months before the onset of rhabdomyolysis. In 12 cases (23%) rhabdomyolysis occurred within 10 days after starting azithromycin in treatment. The reported statin doses were within the recommended daily doses [5, 6] with the exception of one patient, who had switched drug therapy from simvastatin to cerivastatin and by mistake taken the defined daily dose (0.8 mg) of cerivastatin, although twice daily. In one report it was explicitly noted that atorvastatin levels were increased, but plasma levels were not stated. In 12 cases azithromycin and the statin were the sole reported drugs. Of the remaining 41 reports, an established interacting agent [5, 6] known to increase the risk for rhabdomyolysis was found in 16 cases. Table 3 lists patient details of all 11 cases where an interaction has been suggested by the reporter, either by explicitly reporting the drug as interacting (n = 3) or providing a comment in the narrative text (n = 8). In total, azithromycin and a statin were both reported as suspected or interacting to cause rhabdomyolysis in 45% of the reports. Figure 1 shows the reporting of azithromycin and statins with rhabdomyolysis from 1994 up to July From 2000 onwards Omega and Omega _025 were both positive, indicating that the DDA was reported more often than expected in comparison with general reporting to VigiBase. The credibility intervals become narrower over time, which indicates a robustness of the values provided. There is a general reporting increase of rhabdomyolysis in particular with statins to VigiBase from 2000 and onwards. Neither a proportional increase nor an absolute such increase was seen for azithromycin alone with rhabdomyolysis. Discussion A statistical method used for detecting interactions in Vigi- Base,Omega,triggered a manual review of the case reports concerning all statins, azithromycin and rhabdomyolysis. Azithromycin has previously been described not to interact with statins [4,9],with the exception of two case reports [10, 11]. The 53 case reports in VigiBase are suggestive that interactions between azithromycin and atorvastatin, cerivastatin, lovastatin, pravastatin, rosuvastatin or simvastatin resulting in rhabdomyolysis may occur.as the reports were received from a variety of countries, this reduces the possibility that the volume of reports was purely due to selective reporting due to country- or region-specific publication bias. The raw number of reports per combination cannot be interpreted as an estimate of incidence, while the raw number is higher than expected based on general reporting of the drug and adverse reactions.this leads to positive disproportionality scores that have proved predictive of emerging but currently recognized ADR issues [27]. It is noteworthy that the reports were not restricted exclusively to the elderly (e.g. >65 years [28]); this, in combination with the fact that no other drugs than azithromycin and the statin was reported in 12 cases, increases the plausibility of an association. The long-term use of statins with a rapid onset within 10 days of rhabdomyolysis from initiation of azithromycin is also indicative of a drug interaction [29, 30]. Nevertheless, there are several alternative explanations to why rhabdomyolysis might occur and be reported after combined azithromycin and statin therapy. It is possible that the rhabdomyolysis onset during statin therapy after initiation of azithromycin could be a coincidental temporal association. Alternatively, the statin may have interacted with other drugs co-prescribed concomitantly, whether listed on the reports or otherwise. Well-established interacting agents such as gemfibrozil, clarithromycin and erythromycin were co-reported in / 68:3 / Br J Clin Pharmacol
5 Azithromycin-statin interaction Table 3 A summary of the 11 case reports in VigiBase of azithromycin statin and rhabdomyolysis for which a drug interaction was suggested by the reporter Case Sex Age Drugs Other information 1 M Azithromycin Uncertainty whether atorvastatin or gemfibrozil was concomitantly used with azithromycin Atorvastatin 2 M Azithromycin 500 mg (1 day) 250 mg (4 days) Both drugs were discontinued. Outcome unknown Atorvastatin 20 mg (2 years) 3 M 41 Azithromycin Atorvastatin levels were increased, although no plasma levels were given. Pharmacokinetic Atorvastatin 40 mg interaction related to CYP activity is discussed in the narrative text 4 F 66 Azithromycin The reporter stated: multifactor cause of rhabdomyolysis including renal dysfunction, use of Atorvastatin 80 mg (3 years) azithromycin atorvastatin and viral infection. Pharmacokinetic interaction due to CYP activity is discussed in the narrative text Nicotinic acid 5 M 56 Azithromycin Atorvastatin and azithromycin discontinued. Patient recovered. Uncertainty whether Atorvastatin Gemfibrozil atorvastatin or gemfibrozil was concomitantly used with azithromycin 6 F 43 Azithromycin (9 days) The patient recovered Cerivastatin 1 dosage form (4 years) 7 M 51 Azithromycin Lovastatin 8 M 56 Azithromycin (5 days) Simvastatin was increased from 40 to 80 mg day 1 since the LDL was elevated. Three weeks Simvastatin 80 mg (4 weeks) Temazepam Nefazodone Isometheptene Fexofenadine (5 days) later the cholesterol was well controlled. The patient was then started on fexofenadine and AZ. Simvastatin, temazepam, nefazodone, isometheptene and fexofenadine were discontinued. The condition started to improve. In the report nefazodone was primarily suspected to be the culprit. However, it was not possible to exclude the contributing factor of azithromycin, since the ADR occurred 5 days after introduction of azithromycin 9 M Azithromycin Simvastatin 10 M 48 Azithromycin (7 days) Simvastatin Patient with diabetes mellitus, coronary artery disease, cardiomyopathy and history of renal failure secondary to diabetes (transplantation 15 years ago). Azithromycin was introduced; a week later the patient was admitted to hospital for acute renal failure, rhabdomyolysis and hepatic insufficiency. It was determined that the acute renal failure was due to rhabdomyolysis, which was caused by the combination of simvastatin and azithromycin. Simvastatin was discontinued. Hepatic insufficiency and rhabdomyolysis revealed, but renal failure persisted 11 F 74 Azithromycin (13 days) Pravastatin 20 mg (2 years) Three days after a 10-day course of azithromycin the patient developed muscle pain. Pravastatin was discontinued and the symptoms resolved. Pharmacokinetic interaction due to CYP activity is discussed in the narrative. The reporter requested if a change in product information was adequate Time intervals listed within parentheses state the duration of drug therapy prior to onset of rhabdomyolysis occurrence. Ω Figure Year 2008 A trend of disproportionality measures with the 95% credibility intervals over time in VigiBase for atorvastatin, cerivastatin, lovastatin, pravastatin, rosuvastatin, simvastatin with azithromycin and rhabdomyolysis cases [2, 4 7, 9]. Various infectious agents may also cause rhabdomyolysis [31], consequently the underlying infection for which azithromycin was given could have led to rhabdomyolysis without any drug effect. Moreover, other risk factors such as decreased renal function and patient obesity were listed on some of the reports and therefore may have contributed to the disease onset. The observed number cases reported for rhabdomyolysis with azithromycin and the individual statins is two to three times greater than the expected number of cases, which leads to positive Omega values, as well as positive lower 95% credibility intervals (Table 1), although for three individual DDAs, cerivastatin, pravastatin and rosuvastatin, the lack of data (low number of reports) is shown by negative statistics for the lower limit of the 95% credibility interval, Omega_025. However, selective underreporting of the DDA combination by reporting of one drug or the other with rhabdomyolysis would lead to an inflated expected count relative to the observed count this bias is one sided and could deflate the Omega value. In our dataset azithro- Br J Clin Pharmacol / 68:3 / 431
6 J. Strandell et al. mycin was co-reported more often with statins than the well-established interacting agent erythromycin. Selective underreporting of already established associations cannot be excluded. However, the quantitative analysis of spontaneous reports is particularly difficult when considering well-established adverse effects of drugs, since increased publicity of specific issues leads to much increased reporting, irrespective of whether there is an underlying causal relationship [32].This has been referred to as notoriety bias [33]. This is clearly the case with statins and rhabdomyolysis [33, 34], due to the worldwide withdrawal of cerivastatin in Consequently, we examined how the reporting of this potential interaction has changed over time. As seen in Figure 1, rhabdomyolysis with azithromycin and the group of statins was already highlighted in the first quarter of 2000, which suggests that the interaction could have been detected at that time if the Omega measure had been available. The positive Omega value preceding the recent statin publicity strongly shows that this association cannot be explained by the peculiarities of statin reporting observed in recent years. The relative reporting of rhabdomyolysis with azithromycin and statins as a group decreases eventually, although the observed reporting remains higher than expected and the influence was more robust over time up to July The potential role for routine screening for emerging positive Omega to aid in drug drug interaction signal detection is clear.the reporting of individual statins and rhabdomyolysis to the database has increased considerably from 2000 and onwards. However, this increase has not been seen for azithromycin alone with rhabdomyolysis. Nevertheless, a drug known to cause a specific adverse reaction is more likely to be reported as suspected than other agents with no or limited established evidence [35]. Consequently, other possible interacting agents may not be reported or identified as suspected or interacting. Therefore there may be patients who appear from the reports to have received solely a statin and had rhabdomyolysis who in fact were co-prescribed azithromycin and the reporter assumed the macrolide was an innocent bystander. Since muscular and liver function disorders may have a similar mechanism involved as rhabdomyolysis, these associations were also analysed (results not shown). Even though some hepatic reactions were more frequently reported with certain statins and azithromycin, no consistent pattern was observed, probably reflecting the fact that muscular and liver function disorders are general reactions, in contrast to the more specific reaction rhabdomyolysis and may have a number of different causes. Although spontaneous reporting systems remain the basis in the early detection of rare and previously unknown ADRs, such data cannot be used to establish a definite causal relationship between drugs and reactions [32]. The inherent limitations also include reporting bias, underreporting, lack of information regarding drug therapy and clinical details. Furthermore, there is no available information on the number of persons at risk. Additionally, more data on the reported cases are often needed to be able to evaluate potential drug interaction signals, this when comparing to routine signal detection. For example, detailed information regarding time relationships between the reactions and the medications and laboratory value are required in order to identify overlapping therapy or increased plasma concentrations. Nevertheless, our analysis of VigiBase is indicative of a possible interaction between azithromycin and statins resulting in rhabdomyolysis. The exact mechanism of statin-induced rhabdomyolysis remains unclear. Pharmacokinetic as well as pharmacodynamic interactions may be involved [36].When treatment is initiated with a drug that inhibits the metabolism of a statin, by inhibiting cytochrome P450 enzyme activity (mainly CYP3A4), the risk for rhabdomyolysis will increase. Although this mechanism is reported for most of the drug interactions caused by macrolides [37], drugs affecting transporter P-glycoprotein, organic anion transporting polypeptide 1B1 (OATP1B1), or other hepatic uptake transporters, membrane transporters can also affect the disposition of statins [38]. Since azithromycin only is a weak inhibitor of CYP3A4 [37], it is possible that other metabolic or transporter mechanism can explain the drug interaction between statins and azithromycin. Azithromycin has previously been reported to increase the bioavailability of ivermectin, a substrate for the transporter P-glycoprotein and CYP3A4 [39]. The effect of azithromycin on these cell membrane transporters and the possible influence on the disposition of statins need to be further explored. In conclusion, our study has demonstrated the usefulness of the newly developed disproportionality measure, Omega, in order to identify drug interactions in spontaneous reporting datasets. Case reports are suggestive of a drug interaction between statins and azithromycin with rhabdomyolysis.the limited evidence base, in combination with our results, motivates further studies of this potential interaction. This is particularly important given the widespread use of statins, the desire on occasion to co-prescribe macrolides, and the seriousness of rhabdomyolysis as an adverse reaction. Competing interests None declared. We thank Johan Hopstadius for his help in producing figures and statistics presented here.the authors are indebted also to the National Centres that contributed data. The opinions and conclusions in this study are not necessarily those of the various centres or of the WHO. REFERENCES 1 Lane R, Phillips M. Rhabdomyolysis. BMJ 2003; 327: / 68:3 / Br J Clin Pharmacol
7 Azithromycin-statin interaction 2 Evans M, Rees A. Effects of HMG-coa reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002; 13: Molden E, Andersson KS, Jacobsen D. Interactions between statins and macrolide antibiotics. Tidsskr Nor Laegeforen 2007; 127: Thompson Micromedex Database. DrugDex Datapharm Communications Ltd. The Medicines Compendium. Electronic Medicine Compendium, Electronic version, Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000; 34: Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995; 29: Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002; 42: Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997; 31: Skrabal MZ, Stading JA, Cannella CA, Monaghan MS. Two cases of rhabdomyolysis associated with high-dose simvastatin. Am J Health Syst Pharm 2003; 60: Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RMA. Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007; 82: Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002; 25: van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000; 56: Szarfman A, Machado SG, O Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA s spontaneous reports database. Drug Saf 2002; 25: Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug drug interaction surveillance. Stat Med 2008; 27: Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 2001; 28: Strandell J, Bate A, Lindquist M, Edwards IR. Drug interaction signal detection in spontaneous reports. Pharmacoepidemiol Drug Saf 2007; 16 (Suppl. 2): S256 (540). 21 Edwards IR, Olsson S. WHO programme global monitoring. In: Pharmacovigilance, eds Mann RD, Andrews EB. Chichester: John Wiley & Sons, Ltd, 2002; Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 2008; 22: Ståhl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 2004; 13: Lindquist M. Use of triage strategies in the WHO signal-detection process. Drug Saf 2007; 30: Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug drug interactions in a spontaneous reports database. Br J Clin Pharmacol 2007; 64: Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Mining Knowl Discovery 2007; 14: Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000; 23: Bentzen N, Bridges-Webb C. An international glossary for general/family practice. Fam Pract 1995; 12: Kogan ADOS. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990; 66: Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165: Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev 2008; 21: Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30: McAdams M, Staffa J, Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2008; 17: Strandell J, Bate A, Lindquist M, Edwards IR; Swedish, Finnish, Interaction X-referencing Drug Drug Interaction Database (SFINX Group). Drug drug interactions a preventable patient safety issue? Br J Clin Pharmacol 2008; 65: Br J Clin Pharmacol / 68:3 / 433
8 J. Strandell et al. 36 Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000; 50: Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47: El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The effect of azithromycin on ivermectin pharmacokinetics a population pharmacokinetic model analysis. PLoS Negl Trop Dis 2008; 2: e / 68:3 / Br J Clin Pharmacol
Key Elements in Adverse Drug Interaction Safety Signals
Drug Saf (2013) 36:63 70 DOI 10.1007/s40264-012-0003-9 ORIGINAL RESEARCH ARTICLE Key Elements in Adverse Drug Interaction Safety Signals An Assessment of Individual Case Safety Reports Johanna Strandell
More informationA Data Mining Approach for Signal Detection and Analysis
SHORT COMMUNICATION Drug Safety 2002; 25 (6): 393-397 0114-5916/02/0006-0393/$25.00/0 Adis International Limited. All rights reserved. A Data Mining Approach for Signal Detection and Analysis Andrew Bate,
More informationReporting Patterns Indicative of Adverse Drug Interactions
ORIGINAL RESEARCH ARTICLE Drug Saf 2011; 34 (3): 253-266 0114-5916/11/0003-0253/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Reporting Patterns Indicative of Adverse Drug Interactions
More informationThis document was created on 07 January 2005 and has been printed from
1 Spontaneous Adverse Event Reporting Information Introduction This document provides information regarding spontaneous adverse event reports received concerning patients taking rosuvastatin, which relates
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationWithdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States
Bull. Natl. Inst. Health Sci., 123 Notes # Withdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States Journal of American Medical Association (JAMA) Statin HMG
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationStatin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System Toshiyuki Sakaeda 1 *, Kaori Kadoyama 1, Yasushi Okuno 2 * 1 Center for
More informationeappendix A. Simulation study parameters
eappendix A. Simulation study parameters Parameter type Notation Values or distributions Definition i {1 20} Indicator for each of 20 monitoring periods N i 500*i Number of exposed patients in each period,
More informationAutomatic extraction of adverse drug reaction terms from medical free text
Automatic extraction of adverse drug reaction terms from medical free text Ola Caster Uppsala Monitoring Centre WHO Collaborating Centre for International Drug Monitoring ISCB 2009, Prague, Czech Republic
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 24 Scientific conclusions Overall
More informationA mong the 20 leading prescription
Safety and Statins: Pharmacologic and Clinical Perspectives Michael B. Bottorff, PharmD A mong the 20 leading prescription drugs in the United States, 3 agents atorvastatin (Lipitor), simvastatin (Zocor),
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More informationUniv.-Doz. Prof. Dr. W. Renner
Pharmacogenetics of statin-inducedinduced myopathies Wilfried Renner Medical University Graz Clinical Institute of Medical and Chemical Laboratory Diagnostics It started with a fungus 1973: Isolation of
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationRHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY
RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY H Nägele (1)*, S.Behrens (1), S. Hashagen (1), M Azizi (2) 1) St. Adolfstift, Medical Clinic, Reinbek, Germany (Director:
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More information1.* Dosage. A. Adults
3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors [Developed, November 1994; Revised, October 1996; September 1997; September 1998; October 1999; November 1999; August 2000; September
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationPrinciples of Signal Detection. Pia Caduff-Janosa MD Annual Course May 2013
Principles of Signal Detection Pia Caduff-Janosa MD Annual Course May 2013 Outline What is a signal? Signal sources Triggers Assessment of potential risk Signal evaluation Outcome 2 Pia Caduff-Janosa,
More informationEvaluation of cases of severe statin-related transaminitis within a large health maintenance organization
The American Journal of Medicine (2005) 118, 618 624 CLINICAL RESEARCH STUDY Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization Evguenia C. Charles,
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationHow to use statins in patients with chronic liver disease
REVIEW CME CREDIT MARK W. RUSSO, MD Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY IRA M. JACOBSON, MD Center for the Study
More informationTable 1. Reports of tendinitis in which a HMG-CoA-reductase inhibitor was the suspect drug. Concomitant Medication. naproxen meloxicam
1.1. HMG-CoA-reductase inhibitors and or Introduction HMG-CoA-reductase inhibitors are widely used for treatment of primary hypercholesterolemia or mixed dyslipidemia and for treatment of homozygote familiar
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationORIGINAL INVESTIGATION. Screening for Statin-Related Toxicity. The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
ORIGINAL INVESTIGATION Screening for Statin-Related Toxicity The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting C. Christopher Smith, MD; Lana I. Bernstein, MD; Roger
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationFenofibrate interaction
Search Query (DRUGGENERICNAME = Avandia ) AND (RECORDTYPE = Case Report ) 1 Documents Exported 1. Fenofibrate interaction First report of an interaction with concomitant rosiglitazone leading to muscular
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationA method for data driven exploration to pinpoint key features in medical data and facilitate expert review
Received: 16 December 2016 Revised: 16 May 2017 Accepted: 14 July 2017 DOI: 10.1002/pds.4285 ORIGINAL REPORT A method for data driven exploration to pinpoint key features in medical data and facilitate
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationThe Logic of Causality. Dr Ruth Savage With acknowledgements to Professor Ralph Edwards
The Logic of Causality Dr Ruth Savage With acknowledgements to Professor Ralph Edwards 1 The logic of causality The need to think about causal relationships logically, ie apply reasoning. Not always straightforward.
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationStatistical methods for knowledge discovery in adverse drug reaction surveillance
Statistical methods for knowledge discovery in adverse drug reaction surveillance Statistical methods for knowledge discovery in adverse drug reaction surveillance G. Niklas Norén Stockholm University
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationPHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR. Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP
PHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP Disclosure Information PHARMACOVIGILANCE Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz,
More information1 DOS CME Course 2011
Statin Myopathy February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation 1 Case 1 50 y/o woman with hyperlipidemia presents with one year history of deep
More informationROSULIP. Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium).
ROSULIP Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium). Tablets Rosulip 20 mg Each tablet contains 20 mg Rosuvastatin (as calcium). Action Rosuvastatin is a selective and
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationDifferent effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin K. T. Kivistö, T. Kantola & P. J. Neuvonen Department of Clinical Pharmacology, University of Helsinki and Helsinki
More informationIncidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
ORIGINAL CONTRIBUTION Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs David J. Graham, MD, MPH Judy A. Staffa, PhD Deborah Shatin, PhD Susan E. Andrade, ScD Stephanie
More informationClinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network
pharmacoepidemiology and drug safety 2012; 21: 494 506 Published online 16 March 2012 in Wiley Online Library (wileyonlinelibrary.com).3199 ORIGINAL REPORT Clinical importance of the drug interaction between
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationPravastatin conversion to atorvastatin
P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology
More informationPrinciples of signal detection. Marie Lindquist
Principles of signal detection Marie Lindquist Pharmacovigilance endpoints What we do should support good decision making in relation to medication therapy to maximise treatment effectiveness to reduce
More informationDrug Use Criteria: 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins)
Texas Vendor Program Use Criteria: 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) Publication History Developed November 1994. Revised March 2018; March 2017; December 2014;
More informationSimvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
More informationTITLE: SAFE USE OF MEDICINES IN ZANZIBAR A
Table of content Acknowledgements Introduction TITLE: SAFE USE OF MEDICINES IN ZANZIBAR A guide for health professionals in detecting and reporting adverse drug reaction. (Beautiful photograph tablets
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationA cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels Maclaine G D, Patel H
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels Maclaine G D, Patel H Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationEffects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese
et al. British Journal of Clinical Pharmacology DOI:.46/j.365-5.3.3.x Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese Ichiro Fukazawa, Naoki Uchida, Eiji Uchida
More informationIntroduction. agents that have, until recently, been the only ones readily available in NZ. A Medline search from January
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP) Peter W.
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationThe cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E
The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationEmerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
REVIEW ARTICLE Risk for Myopathy With Statin Therapy in High-Risk Patients Christie M. Ballantyne, MD; Alberto Corsini, PhD; Michael H. Davidson, MD; Hallvard Holdaas, MD; Terry A. Jacobson, MD; Eran Leitersdorf,
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness analysis of combination statin/ezetimibe therapy for the treatment of elevated low-density lipoprotein cholesterol Gryskiewicz K A, Coleman C I, Gillespie E L, White C M Record Status
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationPharmacologic Characteristics of Statins
Clin. Cardiol. Vol. 26 (Suppl. III), III-32 III-38 (2003) Pharmacologic Characteristics of Statins JAMES M. MCKENNEY, PHARM.D. National Clinical Research, Inc., and School of Pharmacy, Virginia Commonwealth
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationMaia Gavronski*, Daisy Volmer, Sirpa Hartikainen, Alexander Zharkovsky Potential drug interactions with statins: Estonian register-based study
Open Med. 2015; 10: 254-260 Research Article Open Access Maia Gavronski*, Daisy Volmer, Sirpa Hartikainen, Alexander Zharkovsky Potential drug interactions with statins: Estonian register-based study Abstract:
More informationFarmacologia di genere. Prof. Alberto Corsini Università degli Studi di Milano
Farmacologia di genere Prof. Alberto Corsini Università degli Studi di Milano Women have been less enrolled in clinical trials A gender-specific analysis usually is not included in the evaluation of results
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationDRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE
DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE Matthew P. Kosloski, Weihan Zhao, Hong Li, Stanley Subhead Wang, Calibri Joaquin 14pt, Valdes,
More informationActive TB drug-safety management & monitoring
Active TB drug-safety management & monitoring Global TB Programme, WHO, Switzerland 6 August 2015 Pharmacovigilance: definition of science and activities relating to the detection, assessment, understanding
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationStatin inhibition of HMG-CoA reductase: a 3-dimensional view
Atherosclerosis Supplements 4 (2003) 3/8 www.elsevier.com/locate/atherosclerosis Statin inhibition of HMG-CoA reductase: a 3-dimensional view Eva Istvan * Department of Molecular Microbiology, Howard Hughes
More informationEP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC
(19) (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 13(4) EPC (11) EP 2 07 001 A1 (43) Date of publication: 01.07.2009 Bulletin 2009/27 (21) Application number: 07834499.1 (22) Date
More informationCardiovascular Drugs and Therapies HMG CoA a REDUCTASE INHIBITORS (available in Canada)
Trade Name Dosage Forms 10 mg, 20 mg, 40 mg, 80 mg tablets Dosing Range 10-80 mg once daily 2 Dosing Based on Desired LDL Reduction 1,2,3 HMG CoA a REDUCTASE INHIBITORS (available in Canada) LIPITOR, generics
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationRole of Pharmacoepidemiology in Drug Evaluation
Role of Pharmacoepidemiology in Drug Evaluation Martin Wong MD, MPH School of Public Health and Primary Care Faculty of Medicine Chinese University of Hog Kong Outline of Content Introduction: what is
More informationBRITISH BIOMEDICAL BULLETIN
Journal Home Page www.bbbulletin.org BRITISH BIOMEDICAL BULLETIN Original Cost Analysis Study of HMG CoA Inhibitors Sirisha A.* Department of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally,
More informationOnset timing of statin induced musculoskeletal adverse events and concomitant drug associated shift in onset timing of MAEs
Received: 25 July 2018 Accepted: 2 October 2018 DOI: 10.1002/prp2.439 ORIGINAL ARTICLE Onset timing of statin induced musculoskeletal adverse events and concomitant drug associated shift in onset timing
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationA Comparative Study of Data Mining Algorithms used for Signal Detection in FDA AERS Database
J Young Pharm, 2018; 10(4): 444-449 A multifaceted peer reviewed journal in the field of Pharmacy www.jyoungpharm.org www.phcog.net Original Article A Comparative Study of Data Mining Algorithms used for
More informationEvan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Prevymis TM GENERIC NAME Letermovir MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL November 9, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of new
More informationThere is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.
amciclovir amciclovir + Probenecid Probenecid is predicted to increase the exposure to penciclovir, the active metabolite of famciclovir, possibly resulting in increased adverse effects. Evidence is limited
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationIntegrating Effectiveness and Safety Outcomes in the Assessment of Treatments
Integrating Effectiveness and Safety Outcomes in the Assessment of Treatments Jessica M. Franklin Instructor in Medicine Division of Pharmacoepidemiology & Pharmacoeconomics Brigham and Women s Hospital
More informationIssue date: January Review date: November Statins for the prevention of cardiovascular events. Technology Appraisal 94
Issue date: January 2006 Review date: November 2008 Statins for the prevention of cardiovascular events Technology Appraisal 94 Technology Appraisal 94 Statins for the prevention of cardiovascular events
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationCRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets
CRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets COMPOSITION Each film coated tablet contains 10 mg, 20 mg, or 40 mg of rosuvastatin as rosuvastatin calcium. PHARMACEUTICAL FORM Film-coated tablet Round,
More informationEveness Rosuvastatin. Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt)
Eveness Rosuvastatin Composition Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt) Pharmacological properties Pharmacotherapeutic gruoup: HMG CoA reductase inhibitors Pharmacodynamic
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationCOMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona
COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS Dan Malone, RPh, PhD Professor University of Arizona Disclosures I, Daniel Malone, have no financial relationships to disclose
More informationHMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions
BRIEF COMMUNICATION HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions T. HUYNH, 1 D. CORDATO, 2 F. YANG, 5 T. CHOY, 3 K. JOHNSTONE, 1 F. BAGNALL, 1 N. HITCHENS 2 and R.
More informationLongitudinal monitoring of the safety of drugs by using a web based system: the case of pregabalin
pharmacoepidemiology and drug safety 2011; 20: 591 597 Published online 27 April 2011 in Wiley Online Library (wileyonlinelibrary.com).2135 ORIGINAL REPORT Longitudinal monitoring of the safety of drugs
More informationStatins and newly diagnosed diabetes
DOI:10.1111/j.1365-2125.2004.02142.x British Journal of Clinical Pharmacology Statins and newly diagnosed diabetes Susan S. Jick & Brian D. Bradbury Boston Collaborative Drug Surveillance Program, 11 Muzzey
More information